Trial Profile
A Prospective, Observational, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Adherence and Efficacy of Tenofovir/Emtricitabine/Rilpivirine (TDF/FTC/RPV) in HIV Post-Exposure Prophylaxis (PEP)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2019
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 25 Jan 2019 Results (n=162) published in the Journal of Antimicrobial Chemotherapy.
- 27 Oct 2017 Status changed from recruiting to completed, according to the final results presented at the 16th European AIDS Conference.
- 27 Oct 2017 Final results presented at the 16th European AIDS Conference.